华森制药(002907.SZ)：产品完成境内生产药品备案

Core Viewpoint - The company has completed the domestic production drug filing for Apsaglar (甲磺酸雷沙吉兰片) to address the aging population trend, enhancing product usability and readability through larger print and electronic instructions [1] Group 1 - The company has received approval from the National Medical Products Administration for the domestic production of Apsaglar [1] - The initiative aims to improve the readability and usability of product information for elderly consumers [1] - The company is among the first batch of pilot enterprises in Chongqing and the third batch nationally for aging-friendly reforms, reflecting its commitment to social responsibility [1] Group 2 - This move is expected to enhance the company's market competitiveness and open new market opportunities [1] - The company aims to better promote its products and meet market demand through these innovations [1]